IUVA America 2022 Issues & Goals-rev3.xlsx

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S
1	ƒ					Categories
2
3	Panels	Slide #		Category	Total Number of Entries	1. Efficacy Testing	2. Trained Workforce	3. IAQ/ Public Health	4. Standards & Guidelines	5. Regulatory Guidance	6. Proven Safety	7. Proven Performmance	8. Education Outreach	9. Labeling Prod Info	10. New Tech. Research	11. Cost	12. Far UV	13. Installation Commissioning	14. Collaboration

4	WH-OSTP	2	I-1	Develop standard efficacy testing methods for air treatment technologies that promote appropriate labeling and informed use and enable high-quality, standardized, innovative products to come to market in a trusted manner.		✓								✓
5	WH-OSTP	2	I-2	Conduct multidisciplinary epidemiological and implementation research on built environment technologies for reducing disease spread like GUV.				✓							✓
6	WH-OSTP	2	I-3	Establish indoor air quality and built environment interventions like GUV as routine and significant parts of public health and epidemiological strategy				✓				✓
7	WH-OSTP	3	G-1	Expand and train workforce for installation and maintenance of GUV installations			✓
8	WH-OSTP	3	G-2	Develop more affordable form factors and fixtures for GUV including LED lights											✓	✓
9	WH-OSTP	3	G-3	Support innovation in building and infrastructure design, indoor air quality monitors, pathogen sensors, advanced materials, and air disinfection technologies to foster healthy, safe and secure working, learning, and living environments for all				✓							✓
10	WH-OSTP		Total Entries =	6		1	1	3	0	0	0	1	0	1	3	1	0	0	0
11	PNNL	5	I-1	Field evaluations/demonstrations to show technology is safe and effective							✓	✓	✓
12	PNNL	5	I-2	Guidelines + educated workforce to design, install, operate, maintain GUV systems in buildings			✓		✓
13	PNNL	5	I-3	Validate and/or document safety of far-UV direct irradiation before deployment							✓						✓
14	PNNL	6	G-1	Ensure safety of technology in occupiable spaces				✓			✓
15	PNNL	6	G-2	Educated workforce to design, install, operate, and maintain			✓											✓
16	PNNL	6	G-3	Clear guidelines/standards of most effective and efficient combinations of risk mitigation strategies (GUV, ventilation, room air cleaners, etc.) for IAQ and reduced disease transmission				✓	✓
17	PNNL		Total Entries =	6		0	2	2	2	0	3	1	1	0	0	0	1	1	0
18	FDA	8	I-1	Alignment on what are considered medical claims				✓
19	FDA	8	I-2	Addressing ongoing pandemic concerns				✓
20	FDA	9	G-1	Continue to collaborate with the agency to bring safe and effective products to the market		✓					✓	✓							✓
21	FDA		Total Entries =	3		1	0	2	0	0	1	1	0	0	0	0	0	0	1
22	CDC/NIOSH	11	I-1	Continuing to understand the role UV technologies can play throughout local, state, and federal government agencies									✓						✓
23	CDC/NIOSH	11	I-2	Decoupling UV air treatment from UV surface disinfection					✓				✓
24	CDC/NIOSH	11	I-3	Improving guidance for design, installation, commissioning, operation and periodic performance validation		✓			✓									✓
25	CDC/NIOSH	11	I-4	Documenting successful in-duct UV air treatment case studies				✓				✓
26	CDC/NIOSH	12	G-1	Increase knowledge about the benefits/limitations of far UV									✓				✓
27	CDC/NIOSH	12	G-2	Enhance design, installation and operation guidance			✓		✓									✓
28	CDC/NIOSH	12	G-2.1	Focus on end-users and decision makers									✓
29	CDC/NIOSH	12	G-2.2	Cover all accepted/proven UV technologies					✓	✓			✓						✓
30	CDC/NIOSH	12	G-2.3	Establish proven, user-friendly performance verification protocols		✓			✓	✓								✓
31	CDC/NIOSH	12	G-2.4	Provide credentialing for system designers/installers			✓											✓
32	CDC/NIOSH	12	G-3	Take steps toward standard testing and regulation		✓			✓	✓
33	CDC/NIOSH		Total Entries =	11		3	2	1	6	3	0	1	5	0	0	0	1	4	2
34	NIST	14	I-1	Consensus-based standards and test methods		✓			✓
35	NIST	14	I-2	Consistent approaches to conformity assessment		✓			✓	✓				✓
36	NIST	14	I-3	Stakeholder awareness									✓
37	NIST	15	G-1	Sound, widely-accepted standards and test methods for determining efficacy and safety		✓			✓		✓	✓
38	NIST	15	G-2	Coordination among public and private sector stakeholders									✓						✓
39	NIST	15	G-3	Framework for how to leverage progress when addressing the next challenge				✓	✓	✓			✓						✓
40	NIST		Total Entries =	6		3	0	1	4	2	1	1	3	1	0	0	0	0	2
41	OSHA	17	I-1	Universal performance metric –under which conditions will GUV produce IAQ making fewer people sick		✓		✓	✓			✓
42	OSHA	17	I-2	Universal safety metric –UV dosing under which conditions is safe for workers				✓	✓		✓
43	OSHA	147	I-3	Development of measurement techniques for the 2 issues above		✓		✓	✓	✓
44	OSHA	18	G-1	OSHA is actively partnering with academic and governmental groups to support the development of performance and measuring standards		✓		✓	✓			✓							✓
45	OSHA		Total Entries =	4		3	0	4	4	1	1	2	0	0	0	0	0	0	1
46	EPA	27	I-1	EPA faces many challenges in regulating devices because the current regulatory framework does not allow for pre-market review of product safety or efficacy claims and does not address the complexity of devices available on the market today.		✓				✓			✓
47	EPA	27	I-2	Resource constraints limit the ability to undertake regulatory changes at this time.						✓						✓
48	EPA	27	I-3	Device products with claims to control SARS-CoV-2 have continued to expand during the pandemic.		✓									✓
49	EPA	28	I-4	Public health consequences for insufficiently regulated devices.				✓			✓	✓
50	EPA	28	1-4.1	Users may not use prudent disinfection processes if they believe they are protected by these technologies.				✓			✓		✓
51	EPA	28	1-4.2	Users may believe they do not have to follow public health guidance, such as handwashing, wearing masks, social distancing, etc.				✓			✓		✓	✓
52	EPA	28	1.5	Some devices may cause harm:							✓		✓	✓
53	EPA	28	1.5.1	Some UV lights can causeburns of skin/eyes, skin cancer.							✓		✓	✓
54	EPA	28	1.5.2	Some UV light devices generate ozone which can exacerbate asthma and chronic obstructive pulmonary disease.							✓		✓	✓
55	EPA		Total Entries =	9		2	0	3	0	2	6	1	6	4	1	1	0	0	0
56	Federal Panelists		# (Total = 45)	45	45	13	5	16	16	8	12	8	15	6	4	2	2	5	6
57	Federal Panelists		%		100%	28.9%	11.1%	35.6%	35.6%	17.8%	26.7%	17.8%	33.3%	13.3%	8.9%	4.4%	4.4%	11.1%	13.3%
58
59	P-1: Donsky	31	I.1	Candida auris		✓		✓				✓
60	P-1: Donsky	31	I.1.1	Environment is important				✓	✓				✓
61	P-1: Donsky	31	I.1.2	Manual cleaning suboptimal				✓	✓				✓
62	P-1: Donsky	31	I.1.3	UV-C effective		✓		✓				✓
63	P-1: Donsky	31	I.2	Why is UV not being used?				✓	✓	✓			✓
64	P-1: Donsky	31	I.2.1	Cost				✓					✓			✓
65	P-1: Donsky	31	I.2.2	Ease of use				✓					✓			✓
66	P-1: Donsky	31	I.2.3	Evidence		✓						✓	✓
67	P-1: Donsky	31	I.2.4	CDC recommendations and practice guidelines				✓	✓	✓			✓
68	P-1: Donsky	32	G.1	Do-it-yourself test protocol		✓			✓	✓			✓						✓
69	P-1: Donsky	32	G.1.1	Commercial biological indicator spores		✓		✓	✓			✓	✓						✓
70	P-1: Donsky	32	G.1.2	Simple, standard exposure protocol		✓		✓			✓		✓
71	P-1: Donsky	32	G.1.3	Process in-house or send to commercial lab for testing		✓		✓	✓	✓		✓							✓
72	P-1: Donsky	32	G.2	Compare Devices		✓		✓	✓	✓		✓							✓
73	P-1: Donsky	3	G.3	Cost		✓						✓				✓
74	P-1: Donsky	32	G.4	Evidence		✓						✓
75	P-1: Donsky		Total Entries =	16		10	0	12	8	5	1	8	10	0	0	3	0	0	4
76	P-1: Mathew	34	I.1	Infection prevention principles are the building blocks for safer healthcare delivery				✓	✓	✓			✓
77	P-1: Mathew	34	I.2	Challenges in resilient healthcare staffing and systems			✓	✓										✓
78	P-1: Mathew	34	I.3	Turnover of staff/ EVS: requires frequent training and monitoring/ assessment of any drift in cleaning techniques			✓	✓										✓	✓
79	P-1: Mathew	34	I.4	Rise in antimicrobial resistance (AMR)/ novel pathogens		✓		✓	✓			✓			✓				✓
80	P-1: Mathew	34	I.5	Impact of climate change and spread of soil microbes with AMR (floods leading to soil erosions- with exposures and impacting plants/animals and humans)				✓							✓				✓
81	P-1: Mathew	35	G.1	Devices and tools that are automated (less prone to human errors/ drifts in human techniques)		✓		✓							✓				✓
82	P-1: Mathew	35	G.2	Need to tap into AI- gather data and provide real time feedback		✓		✓				✓			✓				✓
83	P-1: Mathew	35	G.3	UV Devices that are safe in healthcare settings (both in acute care and in Long Term Acute Care and Skilled Nursing facilities				✓			✓		✓						✓
84	P-1: Mathew	35	G.4	Devices for other industries : travel and hospitality (global utilization to decrease spread of AMR through land transport/planes/ships)				✓	✓		✓	✓	✓	✓					✓
85	P-1: Mathew	35	G.5	Devices for Community centers/places of worship/recreation/museums/music/opera (singing = airborne spread)				✓	✓		✓	✓	✓	✓					✓
86	P-1: Mathew	35	G.6	Cost effective and access by communities currently faced with health inequities and limited access to healthcare		✓		✓	✓				✓			✓			✓
87	P-1: Mathew		Total Entries =	11		4	2	11	5	1	3	4	5	2	4	1	0	2	9
88	P-1: Blatchley	37	I.1	Lack of standards for design, validation/testing		✓		✓	✓	✓			✓	✓					✓
89	P-1: Blatchley	37	I.1.1	Quantitative link between system characteristics and performance (risk-based approach)		✓		✓	✓	✓	✓	✓	✓	✓	✓	✓			✓
90	P-1: Blatchley	37	I.2	Optimization of UVC exposure		✓		✓	✓	✓	✓	✓	✓	✓	✓				✓
91	P-1: Blatchley	37	I.2.1	Disinfection vs. human exposure		✓		✓	✓	✓	✓	✓	✓	✓	✓				✓
92	P-1: Blatchley	37	I.3	Need for new, efficient UVC sources		✓		✓	✓	✓			✓		✓		✓		✓
93	P-1: Blatchley	37	I.3.1	Higher output power, wavelength selection		✓					✓	✓			✓		✓		✓
94	P-1: Blatchley	38	G.1	Develop standards for design, testing/validation		✓		✓	✓	✓	✓	✓		✓					✓
95	P-1: Blatchley	38	G.2	Develop new, efficient UV sources		✓		✓							✓	✓
96	P-1: Blatchley	38	G.3	Develop UV-based applications across scales		✓		✓	✓	✓	✓	✓			✓				✓
97	P-1: Blatchley		Total Entries =	9		9	0	8	7	7	6	6	5	5	7	2	2	0	8
98	P-1: McPhaul	40	I.1	Communication to the public about its effectiveness: Does it work?				✓	✓	✓	✓	✓	✓	✓					✓
99	P-1: McPhaul	40	I.2	Communication about its safety: Is it safe? Even for children, older adults, the medically fragile and those who are immune compromised?				✓	✓	✓	✓								✓
100	P-1: McPhaul	40	I.3	Who should I believe when considering GUV?				✓	✓	✓	✓		✓	✓					✓